Advanced Recurrent Ovarian Cancer Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Advanced Recurrent Ovarian Cancer Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Advanced Recurrent Ovarian Cancer Pipeline? @ Advanced Recurrent Ovarian Cancer Pipeline Outlook Report

Key Takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report

• In February 2026, A2 Biotherapeutics Inc. initiated a study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A*02 expression.
• DelveInsight’s Advanced Recurrent Ovarian Cancer pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Advanced Recurrent Ovarian Cancer treatment.
• The leading Advanced Recurrent Ovarian Cancer Companies such as Allarity Therapeutics, AP Biosciences Inc., A2 Biotherapeutics Inc., Verismo Therapeutics, Accent Therapeutics and others.
• Promising Advanced Recurrent Ovarian Cancer Therapies such as OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin, and others.

Want to know which companies are leading innovation in Advanced Recurrent Ovarian Cancer? @ Advanced Recurrent Ovarian Cancer Clinical Trials Assessment

The Advanced Recurrent Ovarian Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Advanced Recurrent Ovarian Cancer Pipeline Report also highlights the unmet needs with respect to the Advanced Recurrent Ovarian Cancer.

Advanced Recurrent Ovarian Cancer Overview

Advanced Recurrent Ovarian Cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general. Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. The existing screening tests have a low predictive value contributing further to this misery. Detailed gynecological evaluation along with ultrasound and laboratory marker like cancer antigen-125 (CA-125) assay are the key early detection strategies which have shown no significant beneficial effect in the morbidity or mortality of this cancer.

Advanced Recurrent Ovarian Cancer Emerging Drugs

• 2X-121: Allarity Therapeutics

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic. Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. Some approved PARP inhibitors have recently been shown to be associated with less favorable survival outcomes than initially established. Allarity’s Phase II trial data for stenoparib to date shows that the drug has much less myelotoxicity than the FDA approved PARP inhibitors. Currently, the drug is in the Phase II stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.

• A2B694: A2 Biotherapeutics Inc.

A2B694 is a Tmod™ chimeric antigen receptor (CAR) T cell therapy targeting tumors that express mesothelin (MSLN) but lack the HLA-A*02 antigen. A2B694 is the second autologous cell therapy in clinical development by A2 Bio using its proprietary Tmod™ platform. The Tmod™ platform utilizes a dual-receptor design consisting of an activator that targets tumor cells and a blocker that protects normal cells. This dual-receptor design is intended to provide selective killing of tumor tissues that express mesothelin and have lost the HLA-A*02 gene permanently. This novel design is aimed at tackling the fundamental challenge in solid tumor cancer medicines – the ability to selectively kill tumor cells and protect normal cells. Currently, the drug is in Phase I/II stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.

• ATX-295: Accent Therapeutics

Accent's ATX-295 program is a potential best-in-class inhibitor for KIF18A which may address a large patient population across several cancer indications, including ovarian and triple negative breast cancer (TNBC). KIF18A is a mitotic kinesin motor protein critical for cell division in select tumors with chromosomal instability, but not in healthy cells. KIF18A inhibitor treatment results in rapid cell death for cancers with an abnormal number of chromosomes (aneuploid) in vitro and in vivo, while cells with normal numbers of chromosomes (euploid) are unaffected. Currently, the drug is in Phase I stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.

If you’re tracking ongoing Advanced Recurrent Ovarian Cancer Clinical trials, this press release is a must-read @ Advanced Recurrent Ovarian Cancer Treatment Drugs

Advanced Recurrent Ovarian Cancer Companies

Allarity Therapeutics, AP Biosciences Inc., A2 Biotherapeutics Inc., Verismo Therapeutics, Accent Therapeutics and others.

The Advanced Recurrent Ovarian Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Recurrent Ovarian Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Recurrent Ovarian Cancer Treatment.
• Advanced Recurrent Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Advanced Recurrent Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Recurrent Ovarian Cancer market.

Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Advanced Recurrent Ovarian Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Advanced Recurrent Ovarian Cancer Pipeline Report covers it all – check it out now @ Advanced Recurrent Ovarian Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report

• Coverage- Global
• Advanced Recurrent Ovarian Cancer Companies- Allarity Therapeutics, AP Biosciences Inc., A2 Biotherapeutics Inc., Verismo Therapeutics, Accent Therapeutics and others.
• Advanced Recurrent Ovarian Cancer Therapies- OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin, and others.
• Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Advanced Recurrent Ovarian Cancer Treatment landscape in this detailed analysis @ Advanced Recurrent Ovarian Cancer Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Advanced Recurrent Ovarian Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Recurrent Ovarian Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Mid Stage Products (Phase II)
10. 2X-121: Allarity Therapeutics
11. Early Stage Products (Phase I)
12. ATX-295: Accent Therapeutics
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Advanced Recurrent Ovarian Cancer Key Companies
17. Advanced Recurrent Ovarian Cancer Key Products
18. Advanced Recurrent Ovarian Cancer- Unmet Needs
19. Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
20. Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
21. Advanced Recurrent Ovarian Cancer Analyst Views
22. Advanced Recurrent Ovarian Cancer Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-pipeline-insight

Metastatic Prostate Cancer Clinical Trial Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insights 2026” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in Metastatic Prostate Cancer pipeline landscape. It covers the Metastatic Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Metastatic Prostate Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Metastatic Prostate Cancer Pipeline Outlook

Key Takeaways from the Metastatic Prostate Cancer Pipeline Report

• On March 19, 2026- Aragon Pharmaceuticals Inc. announced a study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]).
• On March 16, 2026- Janssen Research & Development LLC initiated a phase IV study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).
• On March 16, 2026- T.O.A.D. Oncology SA initiated a phase 1/2 study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
• On March 16, 2026- Merck Sharp & Dohme LLC initiated a phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
• On March 06, 2026- AstraZeneca conducted a Phase I/IIa study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
• On March 02, 2026- Novartis Pharmaceuticals initiated a phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
• DelveInsight’s Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Metastatic Prostate Cancer treatment.
• The leading Metastatic Prostate Cancer Companies such as Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, ORIC Pharmaceuticals, Inc, Lantheus, Eli Lilly and Company, Madison Vaccines, Exelixis, Laekna Therapeutics, Regeneron Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, MacroGenics, Modra Pharmaceuticals, RedHill Biopharma, DexTech Medical, Debiopharm, Astellas Pharma, Arvinas, Orion Corporation, CellCentric, Karyopharm Therapeutics, Corcept Therapeutics, OncoC4, Inmune Bio, Celcuity and others.
• Promising Metastatic Prostate Cancer Pipeline Therapies such as Enzalutamide, Cabazitaxel, Ifinatamab Deruxtecan, MK-5684, Aflibercept, HLD-0915, Prednisone, Quinacrine, SR31747A anad others.

Stay ahead with the most recent pipeline outlook for Metastatic Prostate Cancer @ Metastatic Prostate Cancer Treatment Drugs

Metastatic Hormone Refractory Prostate Cancer Overview

Metastatic Hormone-Refractory Prostate Cancer (mHRPC), also known as metastatic castration-resistant prostate cancer (mCRPC), is an advanced stage of prostate cancer in which the disease continues to progress despite the suppression of testosterone to castrate levels. Initially, prostate cancer growth is typically driven by androgens, and hormone therapy is effective in slowing or stopping the disease. However, in mHRPC, cancer cells adapt and continue to grow even in the low-androgen environment. The cancer has also spread beyond the prostate gland to distant sites, most commonly bones and lymph nodes. This stage is associated with more aggressive behavior, increased symptom burden, and limited treatment options, requiring systemic therapies aimed at prolonging survival and improving quality of life.

Metastatic Prostate Cancer Emerging Drugs Profile

• Opevesostat: Merck

Opevesostat is an oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as prostate cancer. By inhibiting CYP11A1 enzyme activity, ODM-208 is designed to suppress the production of all steroid hormones and their precursors that may activate the androgen receptor signaling pathway. Currently, the drug is in Phase III stage of its development for the treatment of Metastatic Prostate Cancer.

• AZD5305: AstraZeneca

AZD5305 is a highly potent and selective inhibitor of PARP1 with 500-fold selectivity for PARP1 over PARP2. When PARP1 is inhibited, it leads to the accumulation of DNA damage, particularly in cells lacking functional HRR pathways. This results in cell death due to the inability to repair critical DNA lesions. AZD5305 inhibits growth in cells with deficiencies in DNA repair, with minimal/no effects in other cells. Currently, the drug is in Phase III stage of its development for the treatment of Metastatic Prostate Cancer.

• SX-682: Syntrix Pharmaceuticals

SX-682 is a potent small-molecule dual-inhibitor of CXCR1 and CXCR2, chemokine receptors pivotal to myeloid cell suppression of cancer surveillance by the adaptive immune system. By blocking the CXCR1/2 pathway, SX-682 inactivates immunosuppressive myeloid cells, thereby cutting off “at the source” dozens of downstream pro-tumor mechanisms mediated by these cells. The inactivation of suppressive myeloid cells liberates effector cells to kill and eliminate cancer cells. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Prostate Cancer.

• Onvansertib: Cardiff Oncology

Onvansertib is a first-in-class, third generation, highly selective, oral Polo like Kinase 1 (PLK1) inhibitor, that is designed to target and inhibit cancer cell division (mitosis). It is an orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, Onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Prostate Cancer.

• JANX007: Janux Therapeutics

JANX007 is lead novel Tumor Activated T Cell Engager (TRACTr). JANX007 is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of tumors and is in the clinic for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The company designed PSMA-TRACTr drug candidate as a single-masked TRACTr in which the PSMA-binding domain is unmasked. The T cell-specific binding domain (CD3e) is masked to help minimize CRS. Currently, the drug is in Phase I stage of its development for the treatment of Metastatic Prostate Cancer.

• ORIC-944: ORIC Pharmaceuticals, Inc

ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit that demonstrates best-in-class drug properties in preclinical studies, including potency, solubility, and pharmacokinetics, with half-life supporting once daily dosing. ORIC-944 was initially evaluated as a single agent in a Phase Ib trial in patients with advanced prostate cancer and demonstrated potential best-in-class drug properties, including clinical half-life of approximately 20 hours, robust target engagement and a favorable safety profile. Currently, the drug is in Phase I stage of its development for the treatment of Metastatic Prostate Cancer.

The Metastatic Prostate Cancer Pipeline Report Provides Insights into-

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Prostate Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer Treatment.
• Metastatic Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Prostate Cancer market

Explore groundbreaking therapies and clinical trials in the Metastatic Prostate Cancer Pipeline @ New Metastatic Prostate Cancer Drugs

Metastatic Prostate Cancer Companies

Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, ORIC Pharmaceuticals, Inc, Lantheus, Eli Lilly and Company, Madison Vaccines, Exelixis, Laekna Therapeutics, Regeneron Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, MacroGenics, Modra Pharmaceuticals, RedHill Biopharma, DexTech Medical, Debiopharm, Astellas Pharma, Arvinas, Orion Corporation, CellCentric, Karyopharm Therapeutics, Corcept Therapeutics, OncoC4, Inmune Bio, Celcuity and others.

Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Metastatic Prostate Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Metastatic Prostate Cancer Market Drivers and Barriers

Scope of the Metastatic Prostate Cancer Pipeline Report

• Coverage- Global
• Metastatic Prostate Cancer Companies- Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, ORIC Pharmaceuticals, Inc, Lantheus, Eli Lilly and Company, Madison Vaccines, Exelixis, Laekna Therapeutics, Regeneron Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, MacroGenics, Modra Pharmaceuticals, RedHill Biopharma, DexTech Medical, Debiopharm, Astellas Pharma, Arvinas, Orion Corporation, CellCentric, Karyopharm Therapeutics, Corcept Therapeutics, OncoC4, Inmune Bio, Celcuity and others.
• Metastatic Prostate Cancer Pipeline Therapies- Enzalutamide, Cabazitaxel, Ifinatamab Deruxtecan, MK-5684, Aflibercept, HLD-0915, Prednisone, Quinacrine, SR31747A anad others.
• Metastatic Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Metastatic Prostate Cancer Pipeline Therapies and clinical trials @ Metastatic Prostate Cancer Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Metastatic Prostate Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Prostate Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Opevesostat: Merck
9. Mid Stage Products (Phase II)
10. SX-682: Syntrix Pharmaceuticals
11. Early Stage Products (Phase I)
12. JANX007: Janux Therapeutics
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Metastatic Prostate Cancer Key Companies
17. Metastatic Prostate Cancer Key Products
18. Metastatic Prostate Cancer- Unmet Needs
19. Metastatic Prostate Cancer- Market Drivers and Barriers
20. Metastatic Prostate Cancer- Future Perspectives and Conclusion
21. Metastatic Prostate Cancer Analyst Views
22. Metastatic Prostate Cancer Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-hormone-refractory-prostate-cancer-pipeline-insight

Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the Recurrent Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Recurrent Glioblastoma Research @ Recurrent Glioblastoma Pipeline Outlook

Key Takeaways from the Recurrent Glioblastoma Pipeline Report

• On March 12, 2026- BioNTech SE initiated a Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous system (CNS) 2021 criteria who have received prior first-line treatment including with at least radiotherapy and temozolomide, with a Karnofsky performance status (KPS) ≥60, adequate organ function, and at least one measurable lesion according to the response assessment in neuro-oncology (RANO) 2.0 criteria.
• On March 12, 2026- Telix Pharmaceuticals (Innovations) Pty Limited initiated a clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a randomized comparison of the combination therapy against standard care.
• On March 02, 2026- Neonc Technologies Inc. announced a Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase 1 is a standard cohort dose escalation 3+3 design used to determine the maximum tolerated dose for Phase 2a. There will be up to 24 patients enrolled in Phase 1.
• DelveInsight’s Recurrent Glioblastoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Recurrent Glioblastoma treatment.
• The leading Recurrent Glioblastoma Companies such as Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
• Promising Recurrent Glioblastoma Pipeline Therapies such as Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab, Bevacizumab, TTAC-0001, Cediranib and others.

Stay informed about the cutting-edge advancements in Recurrent Glioblastoma treatments @ Recurrent Glioblastoma Clinical Trials Assessment

Recurrent Glioblastoma Overview

Recurrent glioblastoma is a possibility that oncologists – and patients – must keep in mind during and after an initial course of treatment. Because it can be difficult to completely remove a tumor during surgery, there is always a possibility that the cancer might come back after a period of remission. As a result, survivors are typically scheduled for follow-up appointments and surveillance imaging every few months after the completion of their initial treatments. Glioblastoma can come back anywhere in the brain or spinal cord. However, most recurrences are found near the site of the original tumor. Without treatment, the median survival with glioblastoma is only a few months, but even with treatment, survival is frequently only around one year. The five-year survival rate from the disease is roughly 5.0%. For people who have surgery to remove as much of the tumor as possible along with radiation and chemotherapy, the overall median survival (the time after which 50% of people have died and 50% are still alive) is only 14 months. There are treatment options for recurrent glioblastoma, though as noted by looking at survival statistics, few of these have led to long-term survival with the disease. Some treatments do improve survival, and several can improve quality of life. That said, many of these newer treatments have only recently been evaluated in humans, and it's too soon to know what the potential long-term benefit may be.

Recurrent Glioblastoma Emerging Drugs Profile

• ASC40: Ascletis

ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumor cells by blocking de novo lipogenesis. In January 2022, Ascletis Pharma Inc. announced the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). The Phase II study, completed in the U.S., in patients with rGBM has shown that the objective response rate (ORR) for ASC40 plus Bevacizumab treatment was 65% including a complete response (CR) of 20% and a partial response (PR) of 45%.

• GX-I7: Genexine

GX-I7 is a long-acting human IL-7 which is essential for homeostatic T cell proliferation and improves lymphopenia, typically induced by chemotherapy or radiation therapy. The safety has been proved via phase I clinical trial in healthy volunteers and phase Ib and Ib/2 Clinical trials are being conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy.

• Olinvacimab: PharmAbcine

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis. It blocks the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis.

• VXM01: VAXIMM AG

VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. A Phase I/II trial evaluating VXM01 in combination with avelumab, a human anti-PD-L1 antibody, for the treatment of glioblastoma is ongoing. The trial is part of a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. VXM01 has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioblastoma.

The Recurrent Glioblastoma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Recurrent Glioblastoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Recurrent Glioblastoma Treatment.
• Recurrent Glioblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Recurrent Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Recurrent Glioblastoma Market

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Recurrent Glioblastoma Unmet Needs

Recurrent Glioblastoma Companies

Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.

Recurrent Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Recurrent Glioblastoma Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

See the latest progress in drug development and clinical research @ Recurrent Glioblastoma Market Drivers and Barriers, and Future Perspectives

Scope of the Recurrent Glioblastoma Pipeline Report

• Coverage- Global
• Recurrent Glioblastoma Companies- Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
• Recurrent Glioblastoma Pipeline Therapies- Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab, Bevacizumab, TTAC-0001, Cediranib and others.
• Recurrent Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Recurrent Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Recurrent Glioblastoma Pipeline Analysis Today! @ Recurrent Glioblastoma Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Recurrent Glioblastoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Recurrent Glioblastoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ASC40: Ascletis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GX-I7: Genexine
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. VXM01: VAXIMM AG
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Recurrent Glioblastoma Key Companies
21. Recurrent Glioblastoma Key Products
22. Recurrent Glioblastoma- Unmet Needs
23. Recurrent Glioblastoma- Market Drivers and Barriers
24. Recurrent Glioblastoma- Future Perspectives and Conclusion
25. Recurrent Glioblastoma Analyst Views
26. Recurrent Glioblastoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/recurrent-glioblastoma-pipeline-insight

HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “HER2 Positive Gastric Cancer Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in HER2 Positive Gastric Cancer pipeline landscape. It covers the HER2 Positive Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Gastric Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in HER2 Positive Gastric Cancer Research @ HER2 Positive Gastric Cancer Pipeline Outlook

Key Takeaways from the HER2 Positive Gastric Cancer Pipeline Report

• On March 17, 2026, Seagen announced a study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
• On March 16, 2026- Daiichi Sankyo conducted a phase 3 clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort.
• On March 11, 2026, Astellas Pharma Global Development, Inc. initiated a study is to check how long people with stomach cancer and GEJ cancer live after treatment with zolbetuximab with pembrolizumab and chemotherapy compared to placebo with pembrolizumab and chemotherapy.
• On March 09, 2026, AstraZeneca announced a phase 3 study is to assess the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.
• DelveInsight’s HER2 Positive Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2 Positive Gastric Cancer treatment.
• The leading HER2 Positive Gastric Cancer Companies such as Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
• Promising HER2 Positive Gastric Cancer Therapies such as YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.

Stay informed about the cutting-edge advancements in HER2-positive gastric cancer treatments @ HER2 Positive Gastric Cancer Clinical Trials Assessment

HER2 Positive Gastric Cancer Overview

Gastric cancer is the sixth most common cancer and the third most common cause of cancer-related death in the world. Early gastric cancer has no associated symptoms; however, some patients with incidental complaints are diagnosed with early gastric cancer. Most symptoms of gastric cancer reflect advanced disease. All physical signs in gastric cancer are late events. In some people with stomach cancer, the cancer cells have too much of a growth-promoting protein called HER2 on their surface. Cancers with increased levels of HER2 are called HER2-positive. Drugs that target the HER2 protein can often be helpful in treating these cancers. Unfortunately, only a minority of patients with gastric cancer who undergo surgical resection will be cured of their disease. Most patients have a recurrence. HER2, also known as ErbB2/Neu, belongs to the EGFR family and is located on human chromosome 17 (17q21); this gene encodes a 185 kDa transmembrane glycoprotein (p185). EGFR family members include HER1, HER2, HER3, and HER4, which are composed of three parts: an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain.

HER2 Positive Gastric Cancer Emerging Drugs

• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.

SHR-A1811 is a novel anti-HER2 antibody-drug conjugate (ADC) that features an optimized molecular design to enhance plasma stability and bystander effect. Hengrui Pharma is currently conducting more than 10 clinical studies of SHR-A1811 from phase 1 to phase 3 to evaluate its safety and efficacy as single agent or combination therapy in a wide variety of cancer indications. Currently, the drug is in Phase III stage of its development for the treatment of HER2-positive Gastric Cancer.

• Cinrebafusp alfa: Pieris Pharmaceuticals

Cinrebafusp alfa (PRS-343) is a 4-1BB/HER2 fusion protein comprising 4-1BB-targeting Anticalin proteins and a HER2-targeting antibody. The drug candidate is currently in phase 2 development for the treatment of HER2-expressing solid tumors. In phase 1 studies, cinrebafusp alfa has shown an acceptable safety profile at all doses tested with no dose-limiting toxicities. The bispecific also showed a dose response and a 4-1BB-driven mechanism of action based on clinical benefit and pharmacodynamic correlates. Currently, the drug is in Phase II stage of its development for the treatment of HER2-positive Gastric Cancer.

• BI-1607: BioInvent International

BI-1607 is an FcγRIIB-blocking antibody that differs from BI-1206 (BioInvent’s clinical-stage FcγRIIB antibody) in that it has been engineered for reduced Fc-binding to FcγRs. Preclinical proof-of-concept data indicate that combined treatment with BI-1607 may both enhance efficacy of current anti-HER2 regimens and increase response rates in patients no longer responding to anti-HER2-directed therapies such as trastuzumab. Currently, the drug is in Phase I/II stage of its development for the treatment of HER2-positive Gastric Cancer.

The HER2 Positive Gastric Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Positive Gastric Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Positive Gastric Cancer Treatment.
• HER2 Positive Gastric Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HER2 Positive Gastric Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Positive Gastric Cancer market.

Learn more about HER2 Positive Gastric Cancer Drugs opportunities in our groundbreaking Research and development projects @ HER2 Positive Gastric Cancer Unmet Needs

HER2 Positive Gastric Cancer Companies

Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.

​​​​​​HER2 Positive Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

HER2 Positive Gastric Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in HER2 Positive Gastric Cancer Treatment by visiting our website @ HER2 Positive Gastric Cancer Market Drivers and Barriers, and Future Perspectives

HER2 Positive Gastric Cancer Companies and Therapies

• BDC-1001: Bolt Therapeutics Inc.
• KN026: Shanghai JMT-Bio Inc.
• YH32367: Yuhan Corporation
• Margetuximab: MacroGenics
• Zanidatamab: Jazz Pharmaceuticals

Scope of the HER2 Positive Gastric Cancer Pipeline Report

• Coverage- Global
• HER2 Positive Gastric Cancer Companies- Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
• HER2 Positive Gastric Cancer Therapies- YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.
• HER2 Positive Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HER2 Positive Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of HER2 Positive Gastric Cancer Pipeline on our website @ HER2 Positive Gastric Cancer Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. HER2-positive Gastric Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2-positive Gastric Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Cinrebafusp alfa: Pieris Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. BI-1607: BioInvent International
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2-positive Gastric Cancer Key Companies
21. HER2-positive Gastric Cancer Key Products
22. HER2-positive Gastric Cancer- Unmet Needs
23. HER2-positive Gastric Cancer- Market Drivers and Barriers
24. HER2-positive Gastric Cancer- Future Perspectives and Conclusion
25. HER2-positive Gastric Cancer Analyst Views
26. HER2-positive Gastric Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight

HER2-Positive Breast Cancer Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive HER2 Positive Breast Cancer Pipeline Report @ HER2 Positive Breast Cancer Pipeline Outlook Report

Key Takeaways from the HER2 Positive Breast Cancer Pipeline Report

• On March 19, 2026- Greenwich LifeSciences Inc. announced a Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart.
• On March 16, 2026- Seagen initiated a study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
• On March 16, 2026- Criterium Inc. initiated a study is a multicenter, single arm, open-label, run-in phase Ib safety cohort with immediate roll over to a phase II clinical trial that will test the combination therapy of tucatinib with alpelisib in subjects with PIK3CA-mutant HER2+ locally advanced unresectable or metastatic breast cancer. Patients with PIK3CA-mutant HR-/HER2+ and HR+/HER2+ breast cancer may enroll, the latter cohort will receive concomitant treatment with standard doses of fulvestrant to block HR signaling. In phase Ib part, we will confirm the tolerability of tucatinib and alpelisib combination and determine the maximum tolerated dose (MTD). In phase II part, we will expand the testing of this drug combination at MTD to determine the PFS rate.
• On March 12, 2026- Jazz Pharmaceuticals announced a phase 2 study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer.
• On March 09, 2026- Ambrx Inc. conducted a Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.
• DelveInsight’s HER2 Positive Breast Cancer Pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for HER2 Positive Breast Cancer treatment.
• The leading HER2 Positive Breast Cancer Companies such as Prestige BioPharma, Jiangsu HengRui Medicine Co., Ltd., Zymeworks Inc., Shanghai EXUMA Biotechnology, ORIC Pharmaceuticals, Formosa Pharmaceuticals, EirGenix, ExpreS2ion Biotechnologies, Theratechnologies, Byondis, Tanvex Biopharma, Roche, Alphamab, Biocad, Shanghai Henlius Biotech, Novartis Pharmaceuticals, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Zydus Cadila and others.
• Promising HER2 Positive Breast Cancer Pipeline Therapies such as Trastuzumab, Paclitaxel, Zanidatamab, Letrozole, Tamoxifen, PTC+Pertuzumab, FEC-T+Pertuzumab, SHR-A1811, Pyrotinib and others.

Discover how the HER2 Positive Breast Cancer Treatment paradigm is evolving @ HER2 Positive Breast Cancer Clinical Trials and Studies

HER2 Positive Breast Cancer Overview

HER2-positive breast cancer is a subtype of breast cancer characterized by the overexpression or amplification of the HER2 (human epidermal growth factor receptor 2) gene. It accounts for approximately 15–20% of all breast cancer cases and tends to be more aggressive than HER2-negative forms. Advances in targeted therapies have significantly improved outcomes for patients with HER2-positive breast cancer, making it one of the most treatable subtypes when detected early. HER2 is a transmembrane receptor tyrosine kinase involved in cell growth and differentiation. Under normal conditions, HER2 plays a role in regulating cell proliferation. In HER2-positive breast cancer, the overexpression of HER2 leads to constant activation of downstream signaling pathways, such as PI3K/AKT and MAPK, driving uncontrolled tumor cell growth and survival. This makes HER2 a key target for therapy, as inhibiting its function can significantly impede cancer progression.

HER2 Positive Breast Cancer Emerging Drugs Profile

• HD201: Prestige BioPharma

Prestige Biopharma’s HD201 is a biosimilar to Roche’s Herceptin (trastuzumab) to be prescribed for the treatment of human epidermal growth factor 2 (HER2) positive breast and metastatic gastric cancer. Trastuzumab targets HER2, which is overexpressed in some types of cancer cells and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells. Currently the drug is in Preregistration stage for its development in HER2 Positive Breast Cancer.

• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.

SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells. Preclinical research results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, enhance efficacy, meet clinical needs, and provide more cancer patients multiple choice. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 Positive Breast Cancer.

• Zanidatamab: Zymeworks Inc.

Zanidatamab is a bispecific antibody, based on Zymeworks' Azymetric™ platform that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. This unique design results in multiple mechanisms of action including dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function leading to encouraging antitumor activity in patients. Zymeworks is developing zanidatamab in multiple Phase I, Phase II and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks has entered into separate agreements with each of BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab throughout various counties around world. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.

• CCT303-406: Shanghai EXUMA Biotechnology

CCT303-406 is EXUMA Biotech's tumor microenvironment restricted (TMR) autologous CAR-T product candidates targeting HER2, which is currently in the Phase I clinical trial in patients with metastatic HER2+ solid tumors. HER2 overexpression is a hallmark of several tumors, including those originating from breast, stomach, bladder, and colon. A significant proportion of patients relapse or become unresponsive to antibody-based products targeting HER2 in early lines of treatment, yet still retain overexpression of HER2. CCT303-406 may be a promising option for this patient population providing T cell-mediated antitumor activity via targeting of HER2. Differentiating itself from other HER2 CAR-T Therapies, CCT303-406 incorporates EXUMA's TMR safety technology, which helps restrict CAR-T activity to the tumor microenvironment potentially reducing the risk of on-target, off-tumor cytotoxicity. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.

The HER2 Positive Breast Cancer Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Positive Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Positive Breast Cancer Treatment.
• HER2 Positive Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HER2 Positive Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Positive Breast Cancer market

Explore groundbreaking therapies and clinical trials in the HER2 Positive Breast Cancer Pipeline @ New HER2 Positive Breast Cancer Drugs

HER2 Positive Breast Cancer Companies

Prestige BioPharma, Jiangsu HengRui Medicine Co., Ltd., Zymeworks Inc., Shanghai EXUMA Biotechnology, ORIC Pharmaceuticals, Formosa Pharmaceuticals, EirGenix, ExpreS2ion Biotechnologies, Theratechnologies, Byondis, Tanvex Biopharma, Roche, Alphamab, Biocad, Shanghai Henlius Biotech, Novartis Pharmaceuticals, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Zydus Cadila and others.

HER2 Positive Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

HER2 Positive Breast Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ HER2 Positive Breast Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the HER2 Positive Breast Cancer Pipeline Report

• Coverage- Global
• HER2 Positive Breast Cancer Companies- Prestige BioPharma, Jiangsu HengRui Medicine Co., Ltd., Zymeworks Inc., Shanghai EXUMA Biotechnology, ORIC Pharmaceuticals, Formosa Pharmaceuticals, EirGenix, ExpreS2ion Biotechnologies, Theratechnologies, Byondis, Tanvex Biopharma, Roche, Alphamab, Biocad, Shanghai Henlius Biotech, Novartis Pharmaceuticals, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Zydus Cadila and others.
• HER2 Positive Breast Cancer Pipeline Therapies- Trastuzumab, Paclitaxel, Zanidatamab, Letrozole, Tamoxifen, PTC+Pertuzumab, FEC-T+Pertuzumab, SHR-A1811, Pyrotinib and others.
• HER2 Positive Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HER2 Positive Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in HER2 Positive Breast Cancer drug development? @ HER2 Positive Breast Cancer Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. HER2 Positive Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2 Positive Breast Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. HD201: Prestige BioPharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Zanidatamab: Zymeworks Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. CCT303-406: Shanghai EXUMA Biotechnology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2 Positive Breast Cancer Key Companies
21. HER2 Positive Breast Cancer Key Products
22. HER2 Positive Breast Cancer- Unmet Needs
23. HER2 Positive Breast Cancer- Market Drivers and Barriers
24. HER2 Positive Breast Cancer- Future Perspectives and Conclusion
25. HER2 Positive Breast Cancer Analyst Views
26. HER2 Positive Breast Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/her2-positive-breast-cancer-pipeline-insight

Feed Additives Market Size, Share, Industry Growth, Market Trends and Forecast 2026-2031 | CAGR of 6.0%

MarketsandMarkets™

Feed Additives Market by Type (Amino Acids, Phosphates, Vitamins, Acidifiers, Carotenoids, Enzymes, Antioxidants, Antibiotics, Phytogenics, Probiotics, and Others), Source, Form, Livestock, End Users, Function, and Region - Global Forecast to 2031

The feed additives market is estimated at USD 50.72 billion in 2026 and is projected to reach USD 67.90 billion by 2031, at a CAGR of 6.0%. The feed additives market is growing steadily, backed by the increasing focus of livestock and poultry producers on enhancing digestion and maintaining the overall productivity of animals. As farms across the region adopt more commercial and intensive production systems, there is a rising need for feed additives (enzymes, probiotics, amino acids, vitamins, minerals, phytogenics, and organic acids). These additives help animals digest feed better, build immunity, reduce stress, and maintain healthy growth.

Market Size and Growth Forecast

• Market Size, 2025 (Value): USD 48.16 Billion
• Market Forecast in 2031 (Value): USD 67.90 Billion
• Growth Rate: CAGR of 6.0% from 2026 to 2031
• Years Considered: 2022–2031
• Base Year: 2025
• Forecast Period: 2026–2031
• Units Considered: Value (USD Million/Billion), Volume (KT)
• Report Coverage: Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=870

Key Takeaways:

• Asia Pacific accounted for 36.8% of the feed additives market in 2025.
• By type, the amino acids segment is estimated to lead the market with a market share of 28% in 2031.
• By source, the synthetic segment is estimated to hold the largest market share in 2025.
• By livestock, the poultry segment is projected to grow at the fastest CAGR during the forecast period.
• By form, the dry segment is estimated to account for a dominant market share in 2025.
• Cargill, Incorporated and ADM were identified as some of the star players in the feed additives market (global), given their global presence and strong product footprint.
• VITALAC and Tex Biosciences (P) Ltd., among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

 

Asia Pacific to exhibit the fastest CAGR in the feed additives market

Asia Pacific is becoming one of the strongest growth markets for feed additives. This is due to the country’s growing livestock sector. As demand for affordable protein sources such as chicken, eggs, fish, and milk increases, the poultry, dairy, and aquaculture farming sectors are experiencing rapid growth. To meet this rising demand, farms across Asia Pacific are producing more feed each year. As a result, livestock growers are transitioning to modern, commercial production systems, which heavily depend on feed additives such as enzymes, probiotics, amino acids, and vitamins. Feed additives help improve digestion, boost immunity, support faster growth, and maintain healthier animals. This rapid increase in commercial feed usage naturally pushes Asia Pacific’s feed additives demand upward.

By type, the amino acids segment to account for leading market share during the forecast period.

The amino acids segment is estimated to hold a significant share of the feed additives market. Amino acids are essential for supporting animal growth, muscle development, and overall performance. Poultry, swine, and aquaculture are three of the fastest-growing livestock sectors globally, all of which depend heavily on amino acids like lysine, methionine, threonine, and tryptophan. These amino acids enhance feed efficiency and help ensure that animals receive balanced nutrition.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=870

By form, dry additives to lead the market during the forecast period.

Dry feed additives hold a significant share of the market because they are easier to handle, store, and transport compared with liquid additives, an important advantage in a region with diverse climates and long supply chains. Dry forms such as powders, granules, and premixes blend smoothly into compound feed, making them highly preferred by feed mills across the US and Asia Pacific, where large-scale feed production is rapidly increasing.

The report profiles key players such as Cargill, Incorporated (US), ADM (US), International Flavors & Fragrances Inc. (US), Evonik Industries AG (Germany), BASF SE (Germany), DSM-Firmenich (Switzerland), Alltech (US), Ajinomoto Co., Inc. (Japan), Novonesis Group (Denmark), Adisseo (France), Jubilant Ingrevia Ltd (India), Nutreco (Netherlands), BRF Global (Brazil), Volac International Ltd. (UK), Kemin Industries, Inc. (US), Lallemand Inc. (Canada), Bentoli (US), Neospark Drugs and Chemicals Pvt. Ltd. (India), Novus International, Inc. (US), and Global Nutrition International (France).

Recent Developments in the Feed Additives Industry:

• October 2025: BASF launched Lutavit A/D3 1000/200 NXT, a next-generation microencapsulated blend of vitamins A and D3 designed to enhance feed efficiency, stability, and sustainability in animal diets.
• September 2025: ADM launched Digest Carb, a dairy nutrition solution designed to optimize rumen starch and fiber utilization. The product aimed to improve efficiency and milk performance, supporting productivity in dairy operations.
• August 2025: To expand its animal nutrition business in the US, Cargill operated the Granger, Washington Feed Mill, enabling livestock producers to access nutritionally balanced feed products and related services. The facility supported Cargill’s efforts to strengthen regional feed supply and enhance customer reach through efficient and reliable operations.

 

Make an Inquiry: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=870

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/feed-additives-market-870.html

Healthcare Information Exchange Market: Connecting the Future of Care

Healthcare Information Exchange Size, Share & Trends by Type (Direct, Query, Consumer), Implementation (Hybrid, Centralised, Federated), Setup (Private, Public), Solution (Portal, Platform), Application (Workflow, Messaging), End User, & Region - Global Forecast to 2029

Browse 526 market data Tables and 53 Figures spread through 413 Pages and in-depth TOC on "Healthcare Information Exchange Market by Type (Direct, Query, Consumer), Implementation (Hybrid, Centralised, Federated), Setup (Private, Public), Solution (Portal, Platform), Application (Workflow, Messaging), End User, & Region - Global Forecast to 2029" View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/healthcare-information-exchange-market-249987292.html

The global healthcare information exchange market, valued at US$1.5 billion in 2023, stood at US$1.7 billion in 2024 and is projected to advance at a resilient CAGR of 10.2% from 2024 to 2029, culminating in a forecasted valuation of US$2.8 billion by the end of the period.

Browse in-depth TOC on "Health Information Exchange Market"

526 - Tables

53 - Figures

435 - Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249987292

Global Healthcare Information Exchange Market Dynamics

Driver: Government initiatives for enhancing patient safety and care

Government initiatives are aiming at enhancing patient care and safety and have significantly increased the demand for health information exchange (HIE) software solutions, driven by the imperative to facilitate seamless data sharing and interoperability among healthcare providers. For example, in the wake of the COVID-19 pandemic, governments worldwide recognized the critical need for efficient information exchange to track the spread of the virus, manage patient care, and coordinate response efforts. Health authorities mandated the rapid implementation of HIE solutions to enable healthcare organizations to share real-time data on infection rates, hospital bed capacity, and vaccination status. Moreover, widespread adoption of electronic health information exchange has the potential to improve healthcare quality and reduce costs. Through the HITECH Act, the federal government provided $2.4 billion to states in US to improve and advance certain aspects of electronic health information exchange. Such initiatives government-led initiatives and the adoption of value-based care models have further fuelled the demand for HIE software solutions.

Restraint: Data privacy and lack of standardized protocols

Data breaches and cybersecurity threats have become prevalent across various industries, including healthcare. For instance, In September 2020, the Vatemo Psychotherapy Center in Finland, was extorted by a threat actor with data that had been stolen in November 2018 and March 2019. Vatemo runs 25 therapy centers across Finland. The records of approximately 36,000 patients, including juveniles, were stolen. Such attack on hospitals and medical service providers restrains the market. Additionally, interoperability challenges pose a significant restraint on the adoption and effectiveness of HIE solutions. Despite efforts to standardize data formats and protocols, healthcare systems often use different technologies and platforms that may not seamlessly integrate with each other. This fragmentation hampers the exchange of health information and limits the utility of HIE solutions in improving care coordination and patient outcomes.

Opportunity: Improving Healthcare Infrastructure in Emerging Market

Improving digital healthcare infrastructure, particularly focusing on health information exchange (HIE) software solutions, holds immense promise for emerging countries, where access to quality healthcare services remains a challenge. Recent instances underscore the significance of such advancements. For example, in countries like India and Kenya, initiatives leveraging HIE software have been launched to streamline patient data management across various healthcare providers.

Key Players

Prominent players in the Health Information Exchange market include Epic Systems Corporation. (US), Oracle (US), InterSystems Corporation (US), Veradigm LLC (US), Medical Information Technology, Inc. (US), HEALTH CATALYST, INC. (US), Chetu Inc. (US), Meditab (US), Siemens Healthineers (Germany), Deloitte (UK), Dreamsoft4u (US), NCrypted Technologies. (India), Glorium Technologies. (US), Daffodil Unthinkable Software Corporation (US), eClinicalWorks (US), NXGN Management, LLC. (US), Orion Health (New Zealand), Kellton (India), Telstra Health (Australia), CGI Inc. (Canada), Excelicare (US), Octal IT Solution. (US), Andersen (Poland), SISGAIN. (India), Cleverdev Software (US), OSP Labs (US)

Recent Developments of Healthcare Information Exchange Market

• In July 2023, HI-BRIDGE Solutions. (US) partnered with eHealth Exchange network (non-profit organization based in US) to facilitate coordination of care through the exchange of patient clinical data. This partnership with the national exchange will enable the company to expand interoperability and HIE services to support the needs of clinical providers by streamlining the access to vital patient information at point of care.

• In December 2023, Healthix (US) (US) announced its partnership with CLEAR (US) to launch Individual Access Service platform to empower consumers with free, easy, and secure access to healthcare data from more than 8,000 health facilities across New York state in a single portal. This platform provides patient portal technology which embeds CLEAR’s identity verification technology to seamlessly verify a consumer’s identity and provide secure and easy access to their health information.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249987292

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/healthcare-information-exchange-market-249987292.html